Are we getting closer to treating spinal cord injury?📏 The traditional approach to treating these injuries has remained largely focused on rehabilitation and physical therapies that aim to optimize whatever residual function remains. However, these treatments don’t directly address the root causes of nerve damage.🌳 The landscape for spinal cord injury treatments is evolving, with researchers exploring novel approaches like cell therapy, and molecular inhibitors. Labiotech reached out to Brian Culley, CEO of Lineage Cell Therapeutics and Mike Kelly, CEO of NervGen Pharma Corp. to learn more about what could be the future of spinal cord injury treatment.💡 Read the full article below!⬇️ https://lnkd.in/dczW6jHh #Biotech #Biopharma #Spinalcord #Spinalcordinjury #Research #Clinicaltrials #Celltherapy #Peptides #Regenerativemedicine AMERICAN SPINAL INJURY ASSOCIATION | Spinal Injuries Association | Spinal Cord Injury Ontario | Spinal Cord Injury BC | Spinal Cord Injuries Australia
Labiotech.eu
Online Audio- und Videomedien
Berlin, Berlin 22.602 Follower:innen
The leading digital media covering global biotech innovation
Info
Labiotech.eu is the leading digital media covering the global biotech industry. Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Join them now and enjoy reading our stories! "We are building the Next Generation of Digital Media for Biotech" Philip & Joachim, Founders of Labiotech.eu
- Website
-
http://labiotech.eu
Externer Link zu Labiotech.eu
- Branche
- Online Audio- und Videomedien
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Berlin, Berlin
- Art
- Privatunternehmen
- Gegründet
- 2014
- Spezialgebiete
- Biotechnology, Life science, News und Media
Orte
-
Primär
Gotlandstraße 5
Berlin, Berlin 10439, DE
Beschäftigte von Labiotech.eu
Updates
-
Weekly Recap of the Hottest M&A and Partnerships in the Biotech World! 🔥🤝 Merger and acquisition: 🔀 🇺🇸 Genentech to acquire 🇺🇸 Regor Pharmaceuticals’ CDK inhibitors | $850 million upfront payment | Assets acquired: CDK inhibitors for breast cancer 🇺🇸 OncoC4, Inc. and 🇦🇺 🇨🇳 AcroImmune BioTech. Co., Ltd merge | OncoC4 to acquire all outstanding equity interests of AcroImmune | Lead asset: IND-ready PD-1/VEGF bispecific antibody for cancer Partnering: 🤝 🇺🇸 Prime Medicine, Inc. collaborates with 🇺🇸 Bristol Myers Squibb to develop and commercialize prime-edited T-cell therapies | Prime Medicine to receive $110 million upfront and is eligible to receive up to $3.5 billion in milestones 🇺🇸 Generate:Biomedicines collaborates with 🇨🇭 Novartis to discover and develop protein therapeutics | Generate:Biomedicines to receive $65 million upfront and more than $1 billion in milestone payments 🇺🇸 Repair Biotechnologies and 🇨🇦 🇨🇭 Genevant Sciences to collaborate to develop mRNA-LNP therapy | Genevant can receive up to $107 million in upfront and milestone payments Subscribe to our newsletter for more partnering updates! 🔗 https://lnkd.in/dsgz62YY #deals #partnering #mergers #acquisitions #biotech
-
So, which companies managed to raise the biggest private biotech investments in September 2024? 📈 The top spot went to Candid Therapeutics, which launched with a $370 million series A round to develop T-cell engager antibodies. Meanwhile, Arsenal Biosciences, Inc. and eGenesis, Inc. raised the second and third largest rounds, respectively. 🚀 And, after a slow fundraising month in August, things appeared to be back to normal in September, as 11 more rounds took place than in August, with $937 million more raised. 💰 Read our latest article to find out more about last month’s fundraising trends! 👇️ https://lnkd.in/eWkKcJ8i #BiotechInvestments #BiotechFunding #FundraisingTrends #Biopharma #LifeSciences #SeriesARound #BiotechInnovation #InvestmentNews #StartupFunding #BiotechGrowth Aktis Oncology | Superluminal Medicines Inc. | Vicebio | F2G | Circle Pharma, Inc. | Nura Bio | OrsoBio| ONL Therapeutics | GC Therapeutics | Genespire | 858 Therapeutics | Radiant Biotherapeutics | Vironexis Biotherapeutics | Brenus Pharma | Feldan Therapeutics | Epsilogen Ltd
The biggest private biotech investments in September 2024
https://www.labiotech.eu
-
Have you heard of telomerase targeting therapy? 🧬 Telomeres are structures that cap and protect the end of a chromosome. 🛡️ Telomerase is an enzyme that adds DNA to the ends of chromosomes, and is reactivated in most cancers. This makes telomerase a prime target for cancer therapies. 🎯 MAIA Biotechnology, Inc. is exploring telomere targeting through its lead therapeutic strategy, THIO. 💬 On the podcast this week, we have MAIA’s CEO Vlad Vitoc, MD, MBA, discussing MAIA’s clinical work, and the relationships between telomeres, telomerase, and cancer. 🎧 Tune into the latest episode of the Beyond Biotech Podcast to learn more! 👇 https://lnkd.in/d7X5a2uP #BeyondBiotechPodcast #TelomeraseTherapy #cancertreatment #cancerresearch #biotechinnovation #lifesciences
-
💰 Biotech's Top Investments This Week! 🚀 🇺🇸 Kailera Therapeutics | $400 million series A | obesity therapies | phase 2 in obesity and type 2 diabetes 🇺🇸 Wave Life Sciences | $200 million public offering | RNA medicines | clinical in alpha-1 antitrypsin deficiency 🇺🇸 BioAge Labs | $198 million initial public offering | metabolic disease therapies | phase 2 in obesity 🇺🇸 Aktis Oncology | $175 million series B | radiopharmaceuticals | clinical in solid tumors 🇺🇸 858 Therapeutics | $50 million series B | small molecules | phase 1 in solid tumors 🇬🇧 LoQus23 Therapeutics Ltd | £35 million ($43 million) series A | small molecules | preclinical in Huntington's disease 🇺🇸 IN8bio | $12.4 million PIPE | T cell therapies | phase 1 in glioblastoma Subscribe to our newsletter for more fundraising updates! 🔗 https://lnkd.in/dsgz62YY #fundraising #funding #biotech #venturecapital #fundinground #biotechstartup #seriesa #seriesb #seriesc #investors #IPO #seedfunding
-
Did you know that Duchenne muscular dystrophy is among the most severe forms of inherited muscular dystrophy? 🦵 It is caused by a mutation in a gene that codes for the protein dystrophin. 🧬 The condition is estimated to affect one in 3,500 male births worldwide. 👨🦽 In the past few years, therapeutic progress has seen drugs enter the market. Moreover, a variety of medicines are under evaluation, ranging from gene therapies to myosin and HDAC inhibitors. 🏥 In our latest article, we take a look at six biotechs that are fostering R&D in the Duchenne space. 👇 https://lnkd.in/dy6A62YR #DuchenneMuscularDystrophy #DMD #genetherapy #biotechinnovation #healthcarebreakthroughs #biotechnews #lifesciences Wave Life Sciences | Sarepta Therapeutics | Capricor Therapeutics, Inc. | Edgewise Therapeutics | Italfarmaco | Avidity Biosciences, Inc.
Six biotechs driving progress in Duchenne muscular dystrophy
https://www.labiotech.eu
-
European biotech: 10 startups to watch in 2024.
European biotech: 10 startups to watch in 2024
Labiotech.eu auf LinkedIn
-
Is macrophage therapy the key to curing late-stage liver disease? 👀 Resolution Therapeutics just secured $85 million in series B financing to advance RTX001, their engineered macrophage therapy, into clinical trials. With no effective treatments beyond liver transplants, RTX001 could represent a first-in-class therapy by leveraging the body’s immune system to combat inflammation and fibrosis. 🦠 As the EMERALD study begins, this financing also supports pipeline growth and manufacturing improvements. 💸 Read more in our latest article! ⬇️ https://lnkd.in/eZ9NQ52h #macrophagetherapy #liverdisease #RTX001 #inflammation #fibrosis #immunotherapy #biotechinnovation #liverhealth #healthcarebreakthrough #biotechnews Amir Hefni
Resolution Therapeutics raises $85 million to advance its macrophage therapy
https://www.labiotech.eu
-
🧬 Have you ever heard of Niemann-Pick disease? It is a rare genetic lysosomal storage disorder that results in progressive neurological symptoms and organ dysfunction, and is ultimately fatal, as individuals affected only live for around 13 years on average. 💔 But there is finally some good news for patients affected by this devastating disease. The FDA has recently approved the first two treatments for it in the space of a week; one is Zevra Therapeutics’ Miplyffa and the other is IntraBio Inc’s Aqneursa. 💊 🔎 Read our latest article to find out more about these approvals! 👇 https://lnkd.in/d6Ap22Cw #NiemannPickdisease #raredisease #geneticdisorders #biotechbreakthrough #healthcareinnovation #pharmanews #patientcare #medicalresearch
Niemann-Pick disease: FDA approves first two drugs in the space of a week for rare disorder
https://www.labiotech.eu
-
How can you ensure the success of your ADCs in clinical trials and beyond?💡 Antibody-drug conjugates are highly effective cancer treatments, but their intricate structure demands extensive product characterization. Partnering with an experienced CDMO like KBI Biopharma can help ensure rigorous analysis, seamless regulatory filings, and successful commercialization. Discover the approaches KBI Biopharma uses to deliver accurate ADC characterization and quality control. Check out the full article below ⬇️ https://lnkd.in/dzM9GFbQ #cancertreatment #biotechinnovation #biopharmanews #biotechbreakthroughs #pharmainnovation
ADCs that deliver: The secret lies in rigorous characterization
https://www.labiotech.eu